Free Trial
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel Free LXRX Stock Alerts

Lexicon Pharmaceuticals (LXRX) Financials

Lexicon Pharmaceuticals logo
$1.65 +0.05 (+3.13%)
Closing price 10/15/2026 04:00 PM Eastern
Extended Trading
$1.63 -0.02 (-0.97%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Lexicon Pharmaceuticals

Annual Income Statements for Lexicon Pharmaceuticals

This table shows Lexicon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.68 -131 -123 -120 130 -59 -88 -102 -177 -231 -50
Consolidated Net Income / (Loss)		 -4.68 -131 -123 -121 130 -59 -88 -102 -177 -231 -50
Net Income / (Loss) Continuing Operations		 -4.68 -131 -123 -121 130 -59 -87 -102 -177 -231 -54
Total Pre-Tax Income 		-4.68 -131 -136 -121 124 0.00 -87 -104 -177 -231 -54
Total Operating Income		 1.47 -127 -131 -103 141 -48 -87 -101 -172 -197 -49
Total Gross Profit		 130 79 90 61 319 22 0.30 0.14 1.12 -0.62 144
Total Revenue		 130 79 92 63 322 24 0.30 0.14 1.20 0.00 144
Operating Revenue		 130 79 92 63 322 24 0.30 0.14 1.20 - 144
Total Cost of Revenue		 0.00 0.00 1.90 2.49 3.23 1.93 0.00 0.00 0.09 0.62 0.27
Operating Cost of Revenue		 0.00 0.00 1.90 2.49 3.23 1.93 0.00 0.00 0.09 0.62 0.27
Total Operating Expenses		 129 206 220 164 177 70 87 101 173 243 205
Selling, General & Admin Expense		 24 43 66 64 57 47 32 48 114 159 46
Research & Development Expense		 95 164 152 100 92 154 55 53 59 84 61
Other Operating Expenses / (Income)		 5.93 -0.70 2.10 - - - - - - - 99
Total Other Income / (Expense), net		 -6.15 -4.27 -5.03 -17 -17 -11 0.13 -2.78 -5.37 12 7.07
Interest & Investment Income		 - - - - - - - - - - 0.16
Other Income / (Expense), net		 0.57 2.29 1.95 3.51 3.35 2.77 0.13 -2.78 -5.37 12 6.91
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - -0.21 -0.10 - - - - - 0.09
Basic Earnings per Share		 ($0.05) ($1.27) ($1.17) ($1.14) $1.23 ($0.53) ($0.60) ($0.62) ($0.80) ($0.63) ($0.14)
Weighted Average Basic Shares Outstanding		 103.59M 103.86M 105.24M 105.83M 106.22M 110.84M 145.65M 165.73M 221.13M 320.03M 363.05M
Diluted Earnings per Share		 ($0.05) ($1.27) ($1.17) ($1.14) $1.16 $0.00 ($0.60) ($0.62) ($0.80) ($0.63) ($0.14)
Weighted Average Diluted Shares Outstanding		 103.59M 103.86M 105.24M 105.83M 116.75M 0.00 145.65M 165.73M 221.13M 320.03M 363.05M
Weighted Average Basic & Diluted Shares Outstanding		 103.59M 103.86M 105.24M 105.83M 144.35M 144.35M - - 246.24M 361.49M 423.68M

Quarterly Income Statements for Lexicon Pharmaceuticals

This table shows Lexicon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -50 -48 -53 -65 -34 -25 3.25 -13 -16 -1.04 -32
Consolidated Net Income / (Loss)		 -50 -48 -53 -65 -34 -25 3.25 -13 -16 -1.04 -32
Net Income / (Loss) Continuing Operations		 -50 -48 -53 -65 -34 -25 3.25 -12 -20 -1.04 -32
Total Pre-Tax Income 		-50 -48 -53 -65 -46 -25 3.25 -12 -20 -1.04 -32
Total Operating Income		 -47 -45 -55 -64 -33 -26 3.74 -12 -15 -1.00 -27
Total Gross Profit		 0.97 1.10 1.48 1.68 26 1.23 29 42 73 21 0.65
Total Revenue		 1.04 1.13 1.65 1.75 27 1.26 29 42 73 21 0.69
Operating Revenue		 - 1.13 1.65 1.75 27 1.26 29 42 73 21 0.69
Total Cost of Revenue		 0.07 0.03 0.17 0.07 0.35 0.03 0.03 0.01 0.20 0.11 0.04
Operating Cost of Revenue		 0.07 0.03 0.17 0.07 0.35 0.03 0.03 0.01 0.20 0.11 0.04
Total Operating Expenses		 47 46 57 65 59 27 25 55 99 22 27
Selling, General & Admin Expense		 33 32 39 40 32 12 9.35 9.76 15 9.23 9.75
Research & Development Expense		 15 14 18 26 27 15 16 19 11 13 17
Total Other Income / (Expense), net		 -3.02 -3.06 1.93 -1.12 -13 0.38 -0.48 1.59 5.57 -0.05 -5.24
Interest Expense		 - - - - - - 0.00 - - - 4.35
Other Income / (Expense), net		 -3.02 -3.06 1.93 -1.12 -13 0.38 -0.48 1.57 5.44 -0.05 -0.89
Basic Earnings per Share		 ($0.20) ($0.20) ($0.17) ($0.18) ($0.08) ($0.07) $0.01 ($0.04) ($0.04) $0.00 ($0.07)
Weighted Average Basic Shares Outstanding		 221.13M 245.39M 310.84M 361.49M 320.03M 362.07M 363.29M 363.40M 363.05M 400.24M 437.65M
Diluted Earnings per Share		 ($0.20) ($0.20) ($0.17) ($0.18) ($0.08) ($0.07) $0.01 ($0.04) ($0.04) $0.00 ($0.07)
Weighted Average Diluted Shares Outstanding		 221.13M 245.39M 310.84M 361.49M 320.03M 362.07M 363.57M 363.40M 363.05M 400.24M 437.65M
Weighted Average Basic & Diluted Shares Outstanding		 246.24M 246.24M 361.49M 361.49M 361.49M 363.18M 363.40M 363.40M 423.68M 444.20M 444.96M

Annual Cash Flow Statements for Lexicon Pharmaceuticals

This table details how cash moves in and out of Lexicon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 66 -156 15 19 -44 90 -62 -18 -24 44 -3.33
Net Cash From Operating Activities		 185 -176 -185 -149 114 -143 -87 -89 -162 -179 -68
Net Cash From Continuing Operating Activities		 -159 -176 -185 -149 114 -142 -87 -89 -162 -179 -68
Net Income / (Loss) Continuing Operations		 -4.68 -131 -123 -121 130 -59 -88 -102 -177 -200 -50
Consolidated Net Income / (Loss)		 -4.68 -131 -123 -121 130 -59 -88 -102 -177 -200 -50
Depreciation Expense		 0.73 2.06 3.40 3.68 3.65 2.93 0.29 0.43 0.55 0.53 0.62
Amortization Expense		 0.52 0.53 0.60 1.34 1.47 1.01 0.05 0.74 -3.84 -7.46 -2.01
Non-Cash Adjustments To Reconcile Net Income		 10 7.47 9.48 12 43 -118 11 12 16 14 11
Changes in Operating Assets and Liabilities, net		 178 -54 -76 -45 -64 31 -10 0.40 2.66 14 -27
Net Cash From Investing Activities		 -117 18 51 170 -156 381 2.11 -71 -50 -15 113
Net Cash From Continuing Investing Activities		 -117 18 51 170 -156 381 2.11 -71 -50 -15 113
Purchase of Property, Plant & Equipment		 -0.91 -0.23 -0.23 -0.10 -0.07 -0.09 -1.22 -1.33 -0.47 -1.03 0.00
Purchase of Investments		 -326 -426 -268 -120 -322 -59 -34 -134 -223 -329 -140
Sale and/or Maturity of Investments		 210 444 319 290 167 268 38 64 174 314 253
Net Cash From Financing Activities		 -2.03 0.99 150 -2.24 -2.23 -148 23 142 188 238 -48
Net Cash From Continuing Financing Activities		 -2.03 0.99 150 -2.24 -2.23 -148 23 142 188 238 -48
Repayment of Debt		 -1.86 -2.02 -2.28 -15 -1.29 -217 -12 0.00 0.00 -1.31 -48
Issuance of Debt		 0.07 0.00 146 13 0.00 0.00 - 49 50 0.00 0.00
Issuance of Preferred Equity		 - - - - - - - 0.00 0.00 241 0.00
Issuance of Common Equity		 0.11 3.62 7.99 0.73 0.00 70 37 94 139 0.06 0.07
Other Financing Activities, net		 - - - - - - - - -0.82 -1.73 -0.57
Cash Interest Paid		 6.27 6.05 5.87 16 19 17 0.80 2.29 10 13 8.33

Quarterly Cash Flow Statements for Lexicon Pharmaceuticals

This table details how cash moves in and out of Lexicon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 1.35 74 -61 -1.07 32 -3.77 -13 28 -15 3.76 -26
Net Cash From Operating Activities		 -51 -55 -49 -54 -21 -44 17 -24 -17 -15 -9.19
Net Cash From Continuing Operating Activities		 -51 -55 -49 -54 -21 -44 17 -24 -17 -15 -9.19
Net Income / (Loss) Continuing Operations		 -50 -48 -53 -65 -34 -25 3.25 -13 -16 -1.04 -32
Consolidated Net Income / (Loss)		 -50 -48 -53 -65 -34 -25 3.25 -13 -16 -1.04 -32
Depreciation Expense		 0.15 0.14 0.14 0.13 0.13 0.18 0.18 0.15 0.12 0.11 0.10
Amortization Expense		 -1.39 -0.88 -2.79 -2.30 -1.49 -0.93 -0.81 -0.33 0.06 0.12 -0.20
Non-Cash Adjustments To Reconcile Net Income		 4.72 5.48 3.29 3.68 1.87 1.50 3.17 3.43 2.67 2.50 8.17
Changes in Operating Assets and Liabilities, net		 -4.28 -11 4.25 9.69 12 -19 11 -14 -4.55 -16 15
Net Cash From Investing Activities		 52 -110 -12 53 54 41 15 52 4.83 -70 -16
Net Cash From Continuing Investing Activities		 52 -110 -12 53 54 41 15 52 4.83 -70 -16
Purchase of Investments		 -0.10 -183 -77 -43 -26 -65 -26 -27 -22 -106 -57
Sale and/or Maturity of Investments		 52 73 65 96 80 106 41 79 27 36 41
Net Cash From Financing Activities		 -0.00 239 -0.01 -0.92 -0.10 -0.57 -45 - -2.93 89 -0.51
Net Cash From Continuing Financing Activities		 -0.00 239 -0.01 -0.92 -0.10 -0.57 -45 - -2.93 89 -0.51
Repayment of Debt		 - -0.40 - -0.91 -0.00 0.00 -45 - -3.00 -5.00 -57
Issuance of Common Equity		 - 0.09 0.00 - -0.03 0.00 - - 0.07 70 1.02
Cash Interest Paid		 3.29 3.26 3.26 3.28 3.13 2.97 1.92 1.76 1.69 1.48 1.13

Annual Balance Sheets for Lexicon Pharmaceuticals

This table presents Lexicon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 652 476 437 284 418 204 137 194 229 298 185
Total Current Assets		 532 358 322 173 338 158 89 141 177 246 102
Cash & Equivalents		 203 47 62 80 36 126 64 46 22 67 34
Short-Term Investments		 318 300 249 80 236 26 23 92 148 171 62
Accounts Receivable		 0.91 7.49 4.83 5.92 57 0.40 0.01 0.03 1.01 3.47 2.38
Inventories, net		 - 0.00 1.95 4.68 4.24 0.00 0.00 0.00 0.38 0.23 0.28
Other Current Assets		 10 3.88 4.43 2.67 5.32 5.05 2.16 2.48 5.13 4.53 3.00
Plant, Property, & Equipment, net		 21 19 18 16 14 0.30 1.18 2.07 1.99 2.48 1.86
Total Noncurrent Assets		 98 98 97 95 66 46 45 51 51 50 81
Goodwill		 45 45 45 45 45 45 45 45 45 45 45
Other Noncurrent Operating Assets		 0.43 0.46 0.43 0.29 1.66 1.23 0.00 6.82 6.35 5.20 37
Total Liabilities & Shareholders' Equity		 652 476 437 284 418 204 137 194 229 298 185
Total Liabilities		 366 318 368 311 301 47 23 77 136 152 77
Total Current Liabilities		 123 165 105 37 65 47 22 23 32 45 21
Short-Term Debt		 1.98 16 14 1.12 11 12 0.00 - - 0.00 4.60
Accounts Payable		 20 53 39 12 12 5.47 9.15 10 14 15 3.08
Accrued Expenses		 25 32 12 21 42 30 13 13 17 30 13
Total Noncurrent Liabilities		 243 154 263 274 235 0.61 1.19 54 105 107 57
Long-Term Debt		 101 85 232 244 234 0.00 0.00 49 100 100 49
Other Noncurrent Operating Liabilities		 14 0.81 0.29 0.24 1.10 0.61 1.19 5.42 5.27 6.92 7.17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 286 157 68 -26 117 156 114 117 93 146 108
Total Preferred & Common Equity		 286 157 68 -26 117 156 114 117 93 146 108
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 286 157 68 -26 117 156 114 117 93 146 108
Common Stock		 1,398 1,411 1,436 1,448 1,462 1,561 1,609 1,709 1,863 2,118 2,130
Retained Earnings		 -1,109 -1,250 -1,365 -1,472 -1,341 -1,400 -1,488 -1,590 -1,767 -1,967 -2,018
Treasury Stock		 -2.75 -3.37 -1.90 -2.88 -3.82 -4.84 -7.52 -2.06 -2.89 -4.62 -5.19
Accumulated Other Comprehensive Income / (Loss)		 -0.22 -0.20 -0.22 -0.01 0.08 -0.01 -0.01 -0.43 0.03 0.12 0.03

Quarterly Balance Sheets for Lexicon Pharmaceuticals

This table presents Lexicon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 317 276 417 373 321 298 226 206 269 250
Total Current Assets		 264 223 365 321 269 246 145 123 186 197
Cash & Equivalents		 102 21 96 36 35 63 21 50 38 41
Restricted Cash		 - - - - - - - - - 0.00
Short-Term Investments		 154 197 259 274 224 132 118 66 133 150
Accounts Receivable		 0.69 0.32 1.53 2.62 2.90 47 2.18 2.33 12 1.64
Inventories, net		 0.17 0.34 0.51 0.59 0.64 0.20 0.17 0.16 0.28 1.20
Other Current Assets		 6.12 4.29 7.01 7.68 6.71 3.32 3.73 4.09 3.32 3.13
Plant, Property, & Equipment, net		 2.20 2.13 1.84 1.95 2.14 2.31 2.13 1.98 1.75 1.65
Total Noncurrent Assets		 51 51 51 51 50 50 78 81 81 52
Goodwill		 45 45 45 45 45 45 45 45 45 45
Other Noncurrent Operating Assets		 6.26 6.43 6.19 6.02 5.84 5.01 34 37 36 7.29
Total Liabilities & Shareholders' Equity		 317 276 417 373 321 298 226 206 269 250
Total Liabilities		 130 137 128 133 143 175 96 86 66 76
Total Current Liabilities		 26 32 23 28 36 111 35 22 9.90 15
Short-Term Debt		 - - - - - 42 - - 0.00 0.00
Accounts Payable		 11 12 8.07 12 14 11 5.90 3.80 3.00 2.34
Accrued Expenses		 16 20 15 16 22 13 11 14 6.90 12
Total Noncurrent Liabilities		 104 105 105 106 107 64 61 64 56 61
Long-Term Debt		 99 99 100 99 100 59 56 57 50 51
Other Noncurrent Operating Liabilities		 5.48 5.44 5.08 6.00 6.67 5.30 5.20 7.54 6.38 9.39
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 186 140 289 240 179 123 129 120 203 175
Total Preferred & Common Equity		 186 140 289 240 179 123 129 120 203 175
Preferred Stock		 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 186 140 289 240 179 123 129 120 203 175
Common Stock		 1,856 1,860 2,109 2,113 2,116 2,121 2,124 2,127 2,224 2,228
Retained Earnings		 -1,667 -1,717 -1,815 -1,869 -1,933 -1,993 -1,989 -2,002 -2,019 -2,050
Treasury Stock		 -2.89 -2.89 -4.62 -4.62 -4.62 -5.19 -5.19 -5.19 -2.84 -2.84
Accumulated Other Comprehensive Income / (Loss)		 -0.10 -0.11 -0.05 -0.19 0.35 0.03 -0.01 0.03 -0.13 -0.20

Annual Metrics And Ratios for Lexicon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Lexicon Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2020 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 103,622,755.00 104,036,346.00 105,587,794.00 105,925,402.00 106,271,927.00 144,354,161.00 148,895,707.00 188,725,743.00 244,924,695.00 - 363,398,680.00
DEI Adjusted Shares Outstanding		 103,622,755.00 104,036,346.00 105,587,794.00 105,925,402.00 106,271,927.00 144,354,161.00 148,895,707.00 188,725,743.00 244,924,695.00 - 363,398,680.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.05 -1.26 -1.16 -1.14 1.23 -0.41 -0.59 -0.54 -0.72 - -0.14
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 1.03 -89 -33 -72 148 -33 -61 -71 -120 -138 -34
Return On Investment Capital (ROIC_SIMPLE)		 - - - -33.07% 40.93% -19.91% - -42.57% -62.42% -56.03% -21.19%
Earnings before Interest and Taxes (EBIT)		 2.04 -125 -45 -100 145 -45 -87 -104 -177 -213 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.29 -122 -41 -95 150 -41 -87 -102 -180 -220 -43
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 186 -134 -124 -128 116 41 0.00 -71 -115 -124 -91
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -133 -88 3.15 59 91 16 27 27 23 8.29 65
Increase / (Decrease) in Invested Capital		 -185 45 91 55 32 -75 0.00 0.49 -4.75 -14 57
Book Value per Share		 $2.76 $1.51 $0.58 ($0.25) $1.10 $1.33 $0.76 $0.62 $0.38 $0.40 $0.30
Tangible Book Value per Share		 $1.81 $0.57 ($0.24) ($1.14) $0.50 $0.95 $0.46 $0.38 $0.20 $0.28 $0.17
Total Capital		 389 259 314 219 362 168 114 166 193 246 162
Total Debt		 103 101 246 245 245 12 0.00 49 100 100 54
Total Long-Term Debt		 101 85 232 244 234 0.00 0.00 49 100 100 49
Net Debt		 -418 -245 -65 85 -26 -141 -87 -90 -71 -138 -42
Capital Expenditures (CapEx)		 0.58 0.23 -171 0.10 0.07 -171 1.22 1.33 0.47 1.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -110 -137 -80 -22 12 -30 -20 -21 -25 -37 -11
Debt-free Net Working Capital (DFNWC)		 411 210 231 138 283 123 67 118 145 201 86
Net Working Capital (NWC)		 409 193 217 137 272 111 67 118 145 201 81
Net Nonoperating Expense (NNE)		 5.71 42 25 48 18 25 27 31 57 62 16
Net Nonoperating Obligations (NNO)		 -418 -245 -65 85 -26 -141 -87 -90 -71 -138 -42
Total Depreciation and Amortization (D&A)		 1.25 2.58 3.95 5.02 5.12 3.95 0.35 1.17 -3.29 -6.93 -1.39
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.05) ($1.36) ($1.23) ($1.14) $1.23 ($0.53) $0.00 $0.00 ($0.80) ($0.63) ($0.14)
Adjusted Weighted Average Basic Shares Outstanding		 103.77M 104.32M 105.59M 106.27M 106.22M 110.84M 0.00 0.00 221.13M 320.03M 363.05M
Adjusted Diluted Earnings per Share		 ($0.05) ($1.36) ($1.23) ($1.14) $1.16 ($0.53) $0.00 $0.00 ($0.80) ($0.63) ($0.14)
Adjusted Weighted Average Diluted Shares Outstanding		 103.77M 104.32M 105.59M 106.27M 116.75M 110.84M 0.00 0.00 221.13M 320.03M 363.05M
Adjusted Basic & Diluted Earnings per Share		 ($0.05) ($1.36) ($1.23) ($1.14) $1.23 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 103.59M 103.86M 105.24M 105.83M 106.97M 144.35M 0.00 0.00 246.24M 361.49M 423.68M
Normalized Net Operating Profit after Tax (NOPAT)		 3.55 -89 -125 -72 119 -125 -61 -71 -120 -138 -34
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Lexicon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Lexicon Pharmaceuticals' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 244,924,695.00 246,236,753.00 246,236,753.00 361,492,295.00 - 361,492,295.00 363,178,000.00 363,398,860.00 363,398,680.00 423,680,611.00 444,196,390.00
DEI Adjusted Shares Outstanding		 244,924,695.00 246,236,753.00 246,236,753.00 361,492,295.00 - 361,492,295.00 363,178,000.00 363,398,860.00 363,398,680.00 423,680,611.00 444,196,390.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.20 -0.20 -0.22 -0.18 - -0.07 0.01 -0.04 -0.04 0.00 -0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3,621.43% 0.00% 0.00% 980.25% 2,448.37% 11.68% 1,652.64% 2,273.94% - 1,572.11% -97.60%
EBITDA Growth		 -96.87% -55.70% -26.06% -25.52% 19.25% 47.00% 104.66% 83.89% - 96.87% -1,152.06%
EBIT Growth		 -89.87% -51.55% -18.98% -28.28% 19.88% 47.73% 106.09% 83.62% - 95.88% -943.36%
NOPAT Growth		 -54.36% -45.57% -25.12% -28.33% 29.95% 43.35% 109.64% 80.87% - 96.12% -597.27%
Net Income Growth		 -63.17% -51.55% -18.98% -28.28% 32.14% 47.73% 106.09% 80.30% - 95.88% -1,077.09%
EPS Growth		 0.00% -17.65% 22.73% 14.29% 60.00% 65.00% 105.88% 77.78% - 100.00% -800.00%
Operating Cash Flow Growth		 -134.35% -74.39% -27.34% -28.83% 57.48% 20.59% 135.01% 55.55% - 66.35% -154.09%
Free Cash Flow Firm Growth		 -28.92% -46.97% -48.38% -88.48% 69.19% 59.54% 66.67% -11.15% - -291.18% 44.39%
Invested Capital Growth		 -17.38% 7.07% 3.95% -1.52% -63.30% -12.83% 57.68% 203.01% - 183.41% -24.04%
Revenue Q/Q Growth		 543.21% 8.45% 45.75% 6.25% 1,417.37% -95.25% 2,187.32% 43.92% - -71.01% -96.72%
EBITDA Q/Q Growth		 -10.04% 16.33% -14.13% -19.45% 33.86% 45.08% 110.04% -512.58% - 91.13% -3,281.08%
EBIT Q/Q Growth		 -13.78% 15.81% -10.40% -21.30% 28.93% 45.08% 112.86% -426.38% - 88.84% -2,529.53%
NOPAT Q/Q Growth		 5.83% 3.00% -22.11% -15.06% 48.60% 21.56% 120.78% -328.34% - 93.26% -2,564.66%
Net Income Q/Q Growth		 1.52% 2.73% -10.40% -21.30% 47.90% 25.09% 112.86% -492.65% - 93.28% -2,946.50%
EPS Q/Q Growth		 4.76% 0.00% 15.00% -5.88% 55.56% 12.50% 114.29% -500.00% - 100.00% 0.00%
Operating Cash Flow Q/Q Growth		 -21.45% -9.06% 11.95% -10.46% 59.92% -103.70% 138.82% -240.25% - 14.52% 37.60%
Free Cash Flow Firm Q/Q Growth		 -19.03% -21.32% -17.53% -11.05% 80.54% -59.31% 3.17% -270.31% - 20.31% 86.24%
Invested Capital Q/Q Growth		 11.03% 46.70% -10.95% -32.11% -58.62% 248.47% 61.08% 30.46% - 25.37% -56.83%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 93.28% 97.26% 89.92% 95.94% 98.69% 97.62% 99.89% 99.98% - 99.49% 94.36%
EBITDA Margin		 -5,635.99% -4,348.23% -3,404.92% -3,827.89% -178.58% -2,063.71% 9.06% -25.98% - -3.86% -3,977.17%
Operating Margin		 -4,485.32% -4,011.77% -3,360.90% -3,639.60% -123.28% -2,034.79% 12.94% -29.34% - -4.72% -3,835.26%
EBIT Margin		 -5,517.08% -4,282.92% -3,244.02% -3,703.49% -173.45% -2,004.36% 11.27% -25.55% - -4.94% -3,963.29%
Profit (Net Income) Margin		 -4,775.05% -4,282.92% -3,244.02% -3,703.49% -127.16% -2,004.36% 11.27% -30.74% - -4.94% -4,591.76%
Tax Burden Percent		 86.55% 100.00% 100.00% 100.00% 73.31% 100.00% 100.00% 108.62% - 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 110.76% - 100.00% 115.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 -151.40% -204.52% -323.47% -702.63% -173.71% -1,433.33% 19.89% -49.95% - -9.80% -8,924.64%
ROIC Less NNEP Spread (ROIC-NNEP)		 -130.14% -193.86% -315.50% -688.06% -163.28% -1,429.14% 20.22% -46.06% - -9.48% -8,912.75%
Return on Net Nonoperating Assets (RNNOA)		 99.22% 160.89% 272.64% 600.68% 142.19% 1,213.90% -16.05% 33.61% - 6.26% 6,511.54%
Return on Equity (ROE)		 -52.17% -43.62% -50.82% -101.95% -31.52% -219.42% 3.83% -16.34% - -3.54% -2,413.09%
Cash Return on Invested Capital (CROIC)		 -462.46% -412.96% -480.27% -730.31% -800.96% -386.79% -262.67% -216.67% - -126.29% -65.85%
Operating Return on Assets (OROA)		 -31.35% -34.47% -37.43% -69.02% -20.43% -175.03% 2.20% -9.52% - -2.87% -2,268.37%
Return on Assets (ROA)		 -27.14% -34.47% -37.43% -69.02% -14.97% -175.03% 2.20% -11.46% - -2.87% -2,628.07%
Return on Common Equity (ROCE)		 -52.17% -43.62% -50.82% -101.95% -31.52% -219.41% 3.83% -16.34% - -3.54% -2,413.09%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -67.01% 0.00% 0.00% 0.00% -144.11% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -32 -39 -45 -23 -18 3.74 -8.53 -10 -0.70 -19
NOPAT Margin		 -3,139.72% -2,808.24% -2,352.63% -2,547.72% -86.30% -1,424.35% 12.94% -20.53% - -3.30% -2,684.68%
Net Nonoperating Expense Percent (NNEP)		 -21.26% -10.65% -7.97% -14.57% -10.42% -4.18% -0.33% -3.89% - -0.32% -11.89%
Return On Investment Capital (ROIC_SIMPLE)		 -16.98% -8.16% -11.41% -16.01% -9.31% -8.03% 2.01% -4.83% -6.41% -0.28% -8.22%
Cost of Revenue to Revenue		 6.72% 2.74% 10.08% 4.06% 1.31% 2.38% 0.11% 0.02% - 0.51% 5.64%
SG&A Expenses to Revenue		 3,129.17% 2,837.17% 2,379.60% 2,262.40% 121.48% 919.81% 32.39% 23.49% - 43.76% 1,408.96%
R&D to Revenue		 1,416.70% 1,271.86% 1,071.22% 1,473.14% 100.49% 1,212.60% 54.55% 45.15% - 60.45% 2,520.66%
Operating Expenses to Revenue		 4,545.87% 4,109.03% 3,450.82% 3,735.54% 221.97% 2,132.41% 86.94% 132.11% - 104.21% 3,929.62%
Earnings before Interest and Taxes (EBIT)		 -50 -48 -53 -65 -46 -25 3.25 -11 -9.35 -1.04 -27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -51 -49 -56 -67 -47 -26 2.62 -11 -9.17 -0.81 -28
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.02 2.05 1.72 3.18 1.83 1.35 2.65 4.08 - 3.26 6.11
Price to Tangible Book Value (P/TBV)		 7.72 2.42 2.12 4.24 2.63 2.12 4.05 6.49 - 4.18 8.20
Price to Revenue (P/Rev)		 311.24 253.20 103.91 101.91 8.59 5.34 5.88 4.99 - 4.02 7.83
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 13.47 10.12 6.89 20.41 15.60 2.51 5.60 7.10 - 6.59 26.22
Enterprise Value to Revenue (EV/Rev)		 252.67 143.64 51.05 73.45 4.16 2.32 4.46 4.39 - 3.29 6.81
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.07 0.35 0.41 0.56 0.69 0.82 0.43 0.47 - 0.24 0.29
Long-Term Debt to Equity		 1.07 0.35 0.41 0.56 0.69 0.48 0.43 0.47 - 0.24 0.29
Financial Leverage		 -0.76 -0.83 -0.86 -0.87 -0.87 -0.85 -0.79 -0.73 - -0.66 -0.73
Leverage Ratio		 2.02 1.54 1.62 1.88 2.21 1.74 1.62 1.76 - 1.74 1.56
Compound Leverage Factor		 2.02 1.54 1.62 1.88 2.21 1.74 1.62 1.95 - 1.74 1.81
Debt to Total Capital		 51.66% 25.69% 29.31% 35.88% 40.73% 45.01% 30.24% 31.99% - 19.67% 22.76%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 18.80% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 51.66% 25.69% 29.31% 35.88% 40.73% 26.21% 30.24% 31.99% - 19.67% 22.76%
Preferred Equity to Total Capital		 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 48.34% 74.30% 70.69% 64.12% 59.27% 54.99% 69.76% 68.01% - 80.32% 77.24%
Debt to EBITDA		 -0.53 -0.49 -0.46 -0.43 -0.46 -0.51 -0.41 -0.69 - -2.74 -1.06
Net Debt to EBITDA		 0.37 1.24 0.97 0.69 0.63 0.48 0.60 0.73 - 6.66 2.88
Long-Term Debt to EBITDA		 -0.53 -0.49 -0.46 -0.43 -0.46 -0.30 -0.41 -0.69 - -2.74 -1.06
Debt to NOPAT		 -0.83 -0.77 -0.72 -0.68 -0.73 -0.81 -0.68 -1.21 - -2.93 -1.35
Net Debt to NOPAT		 0.59 1.96 1.53 1.07 1.00 0.76 1.00 1.27 - 7.13 3.65
Long-Term Debt to NOPAT		 -0.83 -0.77 -0.72 -0.68 -0.73 -0.47 -0.68 -1.21 - -2.93 -1.35
Altman Z-Score		 -9.20 -2.72 -4.67 -5.82 -7.78 -8.43 -9.31 -9.28 - -3.12 -1.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.01% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.60 15.58 11.51 7.45 5.44 2.22 4.16 5.64 - 18.79 13.37
Quick Ratio		 5.42 15.26 11.21 7.25 5.34 2.19 4.05 5.45 - 18.43 13.07
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -28 -34 -40 -44 -8.61 -14 -13 -49 -67 -54 -7.39
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -17,465.47% -4,533.97% 0.00% 0.00% 0.00% - 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -1.70
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -2.11
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -2.11
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.01 0.02 0.12 0.09 0.20 0.37 - 0.58 0.57
Accounts Receivable Turnover		 2.32 2.61 2.41 3.47 13.87 1.27 24.33 37.57 - 5.55 71.15
Inventory Turnover		 0.00 0.00 0.72 0.70 2.01 1.72 1.28 1.06 - 1.48 0.52
Fixed Asset Turnover		 0.59 1.15 1.92 2.61 13.90 15.04 28.60 47.73 - 80.91 71.96
Accounts Payable Turnover		 0.01 0.01 0.02 0.03 0.04 0.07 0.05 0.05 - 0.05 0.09
Days Sales Outstanding (DSO)		 157.34 139.73 151.51 105.29 26.32 286.34 15.00 9.72 - 65.79 5.13
Days Inventory Outstanding (DIO)		 0.00 0.00 504.21 524.82 181.31 212.17 285.11 344.19 - 247.31 695.34
Days Payable Outstanding (DPO)		 53,212.71 28,913.66 15,133.51 14,166.43 8,648.01 5,565.80 6,860.41 7,801.98 - 7,095.21 4,201.58
Cash Conversion Cycle (CCC)		 -53,055.37 -28,773.93 -14,477.80 -13,536.31 -8,440.37 -5,067.29 -6,560.30 -7,448.08 - -6,782.11 -3,501.11
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 23 33 30 20 8.29 29 47 61 65 82 35
Invested Capital Turnover		 0.05 0.07 0.14 0.28 2.01 1.01 1.54 2.43 - 2.97 3.32
Increase / (Decrease) in Invested Capital		 -4.75 2.19 1.12 -0.31 -14 -4.25 17 41 57 53 -11
Enterprise Value (EV)		 304 335 203 409 129 72 261 431 - 540 927
Market Capitalization		 375 591 414 568 267 167 343 491 - 661 1,066
Book Value per Share		 $0.38 $1.17 $0.97 $0.49 $0.40 $0.34 $0.36 $0.33 $0.30 $0.48 $0.39
Tangible Book Value per Share		 $0.20 $0.99 $0.79 $0.37 $0.28 $0.22 $0.23 $0.21 $0.17 $0.37 $0.29
Total Capital		 193 389 339 278 246 224 186 177 162 253 226
Total Debt		 100 100 99 100 100 101 56 57 54 50 51
Total Long-Term Debt		 100 100 99 100 100 59 56 57 49 50 51
Net Debt		 -71 -256 -210 -158 -138 -94 -83 -59 -42 -121 -139
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.31 0.47 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -14 -17 -26 -37 -18 -29 -15 -11 5.48 -8.74
Debt-free Net Working Capital (DFNWC)		 145 341 293 233 201 177 110 101 86 176 182
Net Working Capital (NWC)		 145 341 293 233 201 135 110 101 81 176 182
Net Nonoperating Expense (NNE)		 17 17 15 20 11 7.32 0.48 4.24 5.18 0.35 13
Net Nonoperating Obligations (NNO)		 -71 -256 -210 -158 -138 -94 -83 -59 -42 -121 -139
Total Depreciation and Amortization (D&A)		 -1.24 -0.74 -2.65 -2.18 -1.36 -0.75 -0.64 -0.18 0.17 0.23 -0.10
Debt-free, Cash-free Net Working Capital to Revenue		 -2,078.49% -614.82% -426.93% -463.44% -119.08% -56.61% -49.22% -15.42% - 3.33% -6.42%
Debt-free Net Working Capital to Revenue		 12,043.27% 14,620.74% 7,359.16% 4,175.97% 646.52% 567.61% 188.68% 102.63% - 107.21% 133.61%
Net Working Capital to Revenue		 12,043.27% 14,620.74% 7,359.16% 4,175.97% 646.52% 432.87% 188.68% 102.63% - 107.21% 133.61%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($0.20) ($0.17) ($0.18) ($0.08) ($0.07) $0.01 ($0.04) ($0.04) $0.00 ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 221.13M 245.39M 310.84M 361.49M 320.03M 362.07M 363.29M 363.40M 363.05M 400.24M 437.65M
Adjusted Diluted Earnings per Share		 ($0.20) ($0.20) ($0.17) ($0.18) ($0.08) ($0.07) $0.01 ($0.04) ($0.04) $0.00 ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 221.13M 245.39M 310.84M 361.49M 320.03M 362.07M 363.57M 363.40M 363.05M 400.24M 437.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 246.24M 246.24M 361.49M 361.49M 361.49M 363.18M 363.40M 363.40M 423.68M 444.20M 444.96M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -32 -39 -45 -23 -18 2.62 -8.53 -10 -0.70 -19
Normalized NOPAT Margin		 -3,139.72% -2,808.24% -2,352.63% -2,547.72% -86.30% -1,424.35% 9.06% -20.53% - -3.30% -2,684.68%
Pre Tax Income Margin		 -5,517.08% -4,282.92% -3,244.02% -3,703.49% -173.45% -2,004.36% 11.27% -28.30% - -4.94% -4,591.76%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -6.31
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -4.27
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -6.31
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 -4.27
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 -0.47% 0.00% 0.00% 0.00% -0.86% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lexicon Pharmaceuticals’ Q2 2026 statements show a well-capitalized but still loss-making biotechnology company. Revenue fell sharply to $0.7 million from $21.1 million in Q1 2026, $28.9 million in Q2 2025 and $72.8 million in Q4 2025. The decline pushed operating income to a loss of $26.5 million and net loss to $31.8 million, compared with a $1.0 million net loss in Q1 2026 and net income of $3.3 million in Q2 2025.

Lexicon’s liquidity remains its primary financial strength. At June 30, 2026, the company held $40.9 million in cash and $149.7 million in short-term investments, or approximately $190.0 million of readily available liquidity. Total current assets of $196.6 million compared with current liabilities of $14.7 million, producing a very strong current ratio of roughly 13.4. However, liquidity has declined from approximately $300.0 million in Q1 2024 and $263.9 million in Q3 2024 as the company has funded operations, repaid debt and invested in securities.

Cash usage has moderated from the severe burn rates reported in 2024 and early 2025. Operating cash flow was negative $9.2 million in Q2 2026, compared with negative $14.7 million in Q1 2026, negative $43.8 million in Q1 2025 and negative $55.1 million in Q1 2024. Still, Lexicon remains dependent on its cash reserves and financing activities because recurring operations are not yet profitable. The balance sheet also reflects substantial accumulated losses, with retained earnings of negative $2.05 billion.

  • Strong liquidity position: Cash and short-term investments totaled approximately $190.0 million at the end of Q2 2026, while current liabilities were only $14.7 million.
  • Improving operating cash burn: Negative operating cash flow improved to $9.2 million in Q2 2026 from $14.7 million in Q1 2026 and $17.2 million in Q4 2025.
  • Debt has declined: Long-term debt was $51.4 million in Q2 2026, down from $99.9 million in Q2 2024 and $56.5 million in Q3 2025. The company reported no short-term debt.
  • Limited capital spending: Net property, plant and equipment was only $1.7 million, suggesting that Lexicon does not require significant capital investment to operate its current business.
  • Balance-sheet equity remains positive: Total equity was $174.5 million at June 30, 2026, exceeding total liabilities of $75.5 million.
  • Revenue is highly volatile: Quarterly revenue increased from $1.0 million in Q4 2023 to $72.8 million in Q4 2025, then fell to $0.7 million in Q2 2026. This pattern may reflect licensing, milestone or other nonrecurring revenue rather than a stable commercial base.
  • Investment portfolio changes drive cash movements: The company regularly purchases and sells short-term investments, creating significant swings in investing cash flow that do not necessarily represent changes in operating performance.
  • Profitability deteriorated materially: Q2 2026 gross profit of $0.7 million was far below operating expenses of $27.2 million, resulting in a $31.8 million net loss and negative diluted earnings per share of $0.07.
  • Research and development spending remains substantial: R&D expense rose to $17.4 million in Q2 2026 from $12.8 million in Q1 2026, while SG&A expense was $9.8 million. These costs require continued funding while revenue remains uncertain.
  • Significant shareholder dilution: Weighted-average basic shares outstanding increased to 437.7 million in Q2 2026 from 363.1 million in Q4 2025 and 221.1 million in Q4 2023, reducing the benefit of any future earnings recovery on a per-share basis.
10/16/26 07:24 AM ETAI Generated. May Contain Errors.

Lexicon Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lexicon Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Lexicon Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$50.34 million in 2025, falling from -$4.68 million in 2015. The previous period was -$231.48 million in 2024. Find out what analysts predict for Lexicon Pharmaceuticals in the coming months.

Lexicon Pharmaceuticals' total operating income in 2025 was -$48.91 million, based on the following breakdown:
  • Total Gross Profit: $144.18 million
  • Total Operating Expenses: $205.49 million

Over the last 10 years, Lexicon Pharmaceuticals' total revenue changed from $130.01 million in 2015 to $144.45 million in 2025, a change of 11.1%.

In the past 12 quarters, Lexicon Pharmaceuticals' cash and equivalents has ranged from $21.12 million in Q3 2023 to $102.27 million in Q2 2023, and is currently $40.92 million as of their latest financial filing in Q2 2026.

Lexicon Pharmaceuticals had total debt of $54.00 million at the end of 2025, a 46.2% decrease from 2024, and a 47.5% decrease since 2015.

Over the last 10 years, Lexicon Pharmaceuticals' book value per share changed from 2.76 in 2015 to 0.30 in 2025, a change of -89.3%.


Related Companies

Financial statements for NASDAQ:LXRX last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...
American Alternative | Sponsoredtc pixel
Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight
A small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...
Digest Publishing | Sponsoredtc pixel
A simple options strategy that changed one trader's path
Ian Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...
TradeWins | Sponsoredtc pixel
Buffett's Final Warning: "The Dollar Is Going to Hell"
Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...
Decentralized Masters | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
Wall Street Legend: “Global Market Freeze Coming”
Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehm...
Weiss Ratings | Sponsoredtc pixel